Delcath Systems, Inc. (NASDAQ:DCTH) Shares Sold by AIGH Capital Management LLC

AIGH Capital Management LLC reduced its stake in shares of Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) by 22.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,385,389 shares of the company's stock after selling 397,101 shares during the quarter. Delcath Systems comprises about 5.2% of AIGH Capital Management LLC's portfolio, making the stock its 6th biggest position. AIGH Capital Management LLC owned 4.33% of Delcath Systems worth $16,680,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently bought and sold shares of DCTH. Quantbot Technologies LP acquired a new position in shares of Delcath Systems in the fourth quarter valued at approximately $66,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Delcath Systems during the 3rd quarter worth approximately $102,000. Barclays PLC bought a new stake in shares of Delcath Systems in the third quarter worth $104,000. Jane Street Group LLC bought a new stake in Delcath Systems during the 3rd quarter worth about $110,000. Finally, Private Advisor Group LLC bought a new position in shares of Delcath Systems in the 4th quarter valued at about $153,000. Institutional investors own 61.12% of the company's stock.

Analyst Ratings Changes

DCTH has been the topic of several recent analyst reports. Craig Hallum boosted their price target on Delcath Systems from $18.00 to $21.00 and gave the stock a "buy" rating in a research report on Friday, January 17th. HC Wainwright increased their price target on shares of Delcath Systems from $22.00 to $24.00 and gave the company a "buy" rating in a research note on Friday, March 7th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Delcath Systems currently has a consensus rating of "Moderate Buy" and a consensus price target of $22.75.

Delcath Systems Stock Performance

Shares of Delcath Systems stock traded down $0.90 during trading on Thursday, reaching $12.08. 258,914 shares of the company's stock were exchanged, compared to its average volume of 443,420. The firm's 50-day moving average price is $14.46 and its 200 day moving average price is $12.09. The company has a market cap of $403.51 million, a P/E ratio of -8.95 and a beta of 0.82. Delcath Systems, Inc. has a 1-year low of $4.26 and a 1-year high of $16.97.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last released its quarterly earnings data on Thursday, March 6th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). Delcath Systems had a negative net margin of 150.70% and a negative return on equity of 338.16%. The firm had revenue of $15.10 million for the quarter, compared to analyst estimates of $14.96 million. During the same period last year, the business earned ($0.48) EPS. As a group, equities research analysts predict that Delcath Systems, Inc. will post -0.79 EPS for the current year.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.